Brian Kieser was appointed as Interim Chief Executive Officer at NEXGEL, INC..
“Effective as of the Separation Date, the Board appointed Brian Kieser to serve as Interim Chief Executive Officer of the Company.”
NEXGEL, INC. — fact timeline
Source-grounded facts extracted from NEXGEL, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Adam R. Levy resigned as Director at NEXGEL, INC..
“Mr. Levy resigned from the Company’s Board of Directors”
Adam R. Levy was terminated as Chief Executive Officer at NEXGEL, INC..
“Effective August 21, 2026 (the “ Separation Date ”), NexGel, Inc. (the “ Company ”) terminated Adam R. Levy’s employment as Chief Executive Officer without Cause (as defined in Mr. Levy’s Executive Employment Agreement, dated July 23, 2026), and Mr. Levy resigned from the Company’s Board of Directors (the “ Board ”) and from all other officer, director, committee and fiduciary positions held by him with the Company and its subsidiaries.”
NEXGEL, INC. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds to the Company of $1,210,000 (effective 2026-05-11).
“Between May 11, 2026 and May 14, 2026, NexGel, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $1,210,000 (the “ Notes ”) and (ii) warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), exercisable for an aggregate of 1,008,334 shares of Common Stock (the “ Warrants ”), in a private placement (the “ Offering ”) for aggregate gross proceeds to the Company of $1,210,000.”
NEXGEL, INC. incurred convertible notes of aggregate original principal amount of $1,210,000 with certain accredited investors.
“investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $1,210,000 (the “ Notes ”) and (ii) warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), exercisable for an aggregate of 1,008,334”
Kevin M. Harris was appointed as Director at NEXGEL, INC..
“On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors”
Brian J. Kieser was appointed as Director at NEXGEL, INC..
“On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors”
Adam Drapczuk resigned as Chief Financial Officer at NEXGEL, INC..
“Mr. Blackman succeeds Mr. Drapczuk as the Company’s principal financial officer and principal accounting officer.”
Ian Blackman was appointed as Chief Financial Officer at NEXGEL, INC..
“the Board of Directors of the Company (the “ Board ”) appointed Ian Blackman, age 58, as Chief Financial Officer of NexGel, Inc. (the “ Company ”), effective April 27, 2026.”
NEXGEL, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“April 22, 2026, NexGel, Inc. (the “ Company ”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for th”
NEXGEL, INC. issued warrant to certain sales representatives of Celularity for conversion of approximately $500,000 of such assumed Sales Rep Obligations.
“certain sales representatives of Celularity whose obligations were assumed by the Company as part of the License Agreement agreed to convert approximately $500,000 of such assumed Sales Rep Obligations into Notes and Warrants issued on identical terms to those issued in the Offering.”
NEXGEL, INC. issued convertible note to certain sales representatives of Celularity for conversion of approximately $500,000 of such assumed Sales Rep Obligations.
“certain sales representatives of Celularity whose obligations were assumed by the Company as part of the License Agreement agreed to convert approximately $500,000 of such assumed Sales Rep Obligations into Notes and Warrants issued on identical terms to those issued in the Offering.”
NEXGEL, INC. issued convertible note to Celularity Inc. for original principal amount of $5,000,000.
“a convertible promissory note issued by the Company to Celularity in the original principal amount of $5,000,000”
NEXGEL, INC. issued exercisable for an aggregate of 5,750,000 shares of Common Stock of warrant to accredited investors (the Buyers) for aggregate gross proceeds to the Company of $6,900,000.
“On April 17, 2026, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000 (the “ Notes ”) and (ii) warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), exercisable for an aggregate of 5,750,000 shares of Common Stock (the “ Warrants ”), in a private placement (the “ Offering ”) for aggregate gross proceeds to the Company of $6,900,000.”
NEXGEL, INC. issued convertible note to accredited investors (the Buyers) for $6,900,000 aggregate gross proceeds.
“On April 17, 2026, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000 (the “ Notes ”) and (ii) warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), exercisable for an aggregate of 5,750,000 shares of Common Stock (the “ Warrants ”), in a private placement (the “ Offering ”) for aggregate gross proceeds to the Company of $6,900,000.”
NEXGEL, INC. incurred convertible notes of original principal amount of $5,000,000 with Celularity Inc. at 10% per annum maturing eighteen (18) months following the issuance date.
“a convertible promissory note issued by the Company to Celularity in the original principal amount of $5,000,000”
NEXGEL, INC. incurred convertible notes of aggregate original principal amount of $6,900,000 with Buyers at 10% per annum maturing eighteen (18) months following the issuance date.
“the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000”
NEXGEL, INC. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate original principal amount of $6,900,000 (effective 2026-04-17).
“On April 17, 2026, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000”
NEXGEL, INC. amended Amendment No. 1 to Asset Purchase and Exclusive License Agreement with Celularity Inc. valued at aggregate consideration in the amount of $13,300,000 (effective 2026-04-17).
“On April 17, 2026, the Company and Celularity entered into Amendment No. 1 to the Original License Agreement (the “ Amendment ” and, together with the Original License Agreement, the “ License Agreement ”).”
NEXGEL, INC. entered into Asset Purchase and Exclusive License Agreement with Celularity Inc. (effective 2026-03-06).
“on March 6, 2026, NexGel, Inc. (the “ Company ”) entered into an Asset Purchase and Exclusive License Agreement (the “ Original License Agreement ”) with Celularity Inc. (“ Celularity ”)”
NEXGEL, INC. completed an acquisition involving Celularity Inc. for $13,300,000 (closed 2026-04-17).
“the grant of rights and the transfer of assets contemplated by the License Agreement, the Company agreed to pay or deliver to Celularity aggregate consideration in the amount of $13,300,000, consisting of (i) an upfront cash payment of $8,300,000, paid on the Transaction Commencement Date (as defined in the License Agreement) in accordance with the flow of funds”
NEXGEL, INC. entered into Agreement with Celularity, Inc. valued at up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million (effective 2026-03-06).
“On March 6, 2026, NexGel, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase and Exclusive License Agreement (the “ Agreement ”) with Celularity, Inc., a Delaware corporation (the “ Licensor ”), whereby the Licensor granted to the Company an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs as more fully described in the Agreement and the Licensor agreed to sell to the Company assets related to the portfolio (collectively, the “ Business ”). Consideration for the Business will consist of up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million upfront payment and (ii) an additional $20.0 million in potential milestone payments based on net sales targets related to the Business.”
NEXGEL, INC. incurred convertible notes of $56,667,667 with a certain institutional investor.
“Agreement ”) providing for the purchase by the Investor of a 10% original issue discount (OID) convertible note facility in up to the aggregate original principal amount of $56,667,667 (the “ Convertible Note Facility ”), providing for the purchase by the Investor, in one or more closings, of (i) series A senior secured convertible notes up to an aggregate”
NEXGEL, INC. entered into Securities Purchase Agreement with a certain institutional investor (effective 2026-02-09).
“On February 9, 2026, NexGel, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement with a certain institutional investor (the “ Investor ”) named therein (the “ Purchase Agreement ”) providing for the purchase by the Investor of a 10% original issue discount (OID) convertible note facility”
Joseph F. McGuire was appointed as Chief Financial Officer at NEXGEL, INC..
“Joseph F. McGuire Appointment as Chief Financial Officer”
NEXGEL, INC. completed an acquisition involving Semmens Online Pty Ltd as Trustee for Semmens Business Trust for $400,000 cash and $200,000 in shares (closed 2024-05-15).
“the tradename “Silly George” (collectively, the “ Business ”). Under the terms of the Purchase Agreement and on the Closing Date, the Company paid the Seller a cash payment of $400,000 (the “ Initial Cash Payment”) and will issue within 5 trading days of the Closing Date $200,000 in shares of the Company’s common stock based on the 10-Day VWAP (as defined in the”
NEXGEL, INC. reported the quarter ended March 31, 2024 results: revenue $1.27 million, net income $905,000.
“as shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle,”
NEXGEL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $4.1 million, net income Net loss for the year ended December 31, 2023, was $3.2 million.
“NEXGEL Reports Full Year 2023 Revenue of $4.1 Million”
NEXGEL, INC. entered into Subscription Agreements with investors, the Company's Chief Financial Officer and certain members of its board of directors valued at approximately $975 thousand (effective 2024-02-15).
“On February 15, 2024, NexGel, Inc., a Delaware corporation (the “ Company ”), entered into subscription agreements (the “ Subscription Agreements ”) with investors, the Company’s Chief Financial Officer and certain members of its board of directors for the sale of by the Company of an aggregate of 231,040 units at a price to the public of $4.22 per unit”
Miranda J. Toledano resigned as Director; Chairperson of Audit Committee; member of Nominating and Corporate Governance Committee at NEXGEL, INC..
“On January 9, 2024, Miranda J. Toledano notified NexGel, Inc. (the “ Company ”) of her intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of March 31, 2024.”
David Stefansky resigned as Director at NEXGEL, INC..
“On December 7, 2023, David Stefansky notified NexGel, Inc. (the “ Company ”) of his intent to resign as a member of the Company’s Board of Directors (the “ Board ”) effective as of December 31, 2023 to pursue other business ventures.”
NEXGEL, INC. completed an acquisition involving Olympus Trading Company, LLC for $546,500 plus Earn-Out Payments (closed 2023-12-01).
“tradename “Kenkoderm” (collectively, the “ Business ”). Under the terms of the Purchase Agreement and on the Closing Date, the Company paid the Seller a cash payment of $546,500 (the “ Initial Cash Payment ”). The Initial Cash Payment is not subject to any escrow conditions. Additionally, the Company shall pay the Seller a cash earn-out paid on a”
NEXGEL, INC. entered into Purchase Agreement with Olympus Trading Company, LLC valued at $546,500 (effective 2023-11-30).
“On December 1, 2023 (the “ Closing Date ”), NexGel, Inc., a Delaware corporation (the “ Company ”) closed a transaction related to an Asset Purchase Agreement dated November 30, 2023 (the “ Purchase Agreement ”) with Olympus Trading Company, LLC, a Virginia limited liability company (the “ Seller ”), whereby the Company purchased all assets related to the Seller’s skincare line”
NEXGEL, INC. reported third quarter ended September 30, 2023 results: revenue $1.2 million, EPS $0.10 per basic and diluted share.
“shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa. – November 13, 2023 – NEXGEL, Inc.”
NEXGEL, INC. reported the quarter ended June 30, 2023 results: revenue $1.17 million, net income $687 thousand or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.
“For the second quarter of 2023, revenue totaled $1.17 million, an increase of $606 thousand or 108%, as compared to $561 thousand for the same period the year prior.”
NEXGEL, INC. shareholders approved To ratify the appointment by the audit committee of the board of directors of Cherry Turner, Stone & Company, L.L.P. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-06 meeting.
“PROPOSAL 3: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CHERRY TURNER, STONE & COMPANY, L.L.P. AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2023. Votes For Votes Against Votes Abstaining 3,088,731 9,153 80”
NEXGEL, INC. shareholders approved To approve the third amendment to the NexGel, Inc. 2019 Long-Term Incentive Plan to increase the total number of shares of common stock authorized for issuance under such plan by 300,000, to a total of 871,429 shares. at the 2023-06-06 meeting.
“PROPOSAL 2: TO APPROVE THE THIRD AMENDMENT TO THE NEXGEL, INC. 2019 LONG-TERM INCENTIVE PLAN TO INCREASE THE TOTAL NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 300,000, TO A TOTAL OF 871,429 SHARES. Votes For Votes Against Votes Abstaining Broker Non-Votes 705,557 196,085 449,514 1,746,808”
NEXGEL, INC. shareholders approved To elect seven directors to serve until the next annual meeting or until their successors are duly elected and qualified. at the 2023-06-06 meeting.
“PROPOSAL 1: TO ELECT SEVEN (7) DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING OR UNTIL THEIR SUCCESSORS ARE DULY ELECTED AND QUALIFIED. Votes For Withheld Broker Non-Votes Steven Glassman 1,339,299 11,857 1,746,808 Scott R. Henry 1,339,328 11,828 1,746,808 Adam Levy 1,339,895 11,261 1,746,808 David Stefansky 1,339,795 11,361 1,746,808 Nachum Stein 1,339,291 11,865 1,746,808 Miranda J. Toledano 1,338,244 12,912 1,746,808 Dr. Jerome Zeldis 1,301,886 49,270 1,746,808”
NEXGEL, INC. reported first quarter ended March 31, 2023 results: revenue $620 thousand, net income $814 thousand or $0.15 per basic and diluted share, EPS $0.15 per basic and diluted share. Guidance initiated.
“First Quarter 2023 Financial Highlights For the first quarter of 2023, revenue totaled $620 thousand and increased by $224 thousand, or 56.6%, compared to $396 thousand for the same period the year prior. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products. Revenue during the first quarter of 2023 includes one full month of revenue contribution from the Company’s newly formed joint venture with C.G. Laboratories. Gross loss for the first quarter of 2023 was $57 thousand, compared to a gross loss of $22 thousand for the same prior year period. The increase in the loss was mainly due to the increased manufacturing of promotional materials and customer product samples to support our new product line growth. Gross margin loss was approximately 9.2% for the three months ended March 31, 2023, compared to a gross margin loss of 5.6% for the three months ended March 31, 2022. Cost of revenues was $677 thousand for the quarter e”
NEXGEL, INC. reported the year ended December 31, 2022 results: revenue $2.05 million.
“For the year ended December 31, 2022, revenue totaled $2.05 million, an increase of $497 thousand, or 32%, when compared to $1.55 million for the year ended December 31, 2021.”
NEXGEL, INC. reported fourth quarter of 2022 results: revenue $524 thousand.
“For the fourth quarter of 2022, revenue totaled $524 thousand, a slight decrease as compared to $533 thousand in the fourth quarter of 2021.”
Yaakov Spinrad resigned as Director at NEXGEL, INC..
“On January 16, 2023, Yaakov Spinrad resigned as a member of the Board.”
Scott R. Henry was appointed as Director at NEXGEL, INC..
“On January 16, 2023, Scott R. Henry (the “ Board Appointees ”) was appointed to the board of directors (the “ Board ”) of NexGel, Inc.”
NEXGEL, INC. reported third quarter ended September 30, 2022 results: revenue $568 thousand.
“demonstrated significant scar improvement in patients treated with SilverSeal. Third Quarter 2022 Financial Highlights Revenue for the three months ended September 30, 2022 was $568 thousand, an increase of 69.6%, when compared to $233 thousand for the three months ended September 30, 2021. The increase in overall revenue was due to sales growth in branded consumer”
Adam Levy was appointed as Director at NEXGEL, INC..
“On September 9, 2021, Yaakov Spinrad, Miranda J. Toledano and Adam Levy (the “ Board Appointees ”) were appointed to the board of directors”
Miranda J. Toledano was appointed as Director at NEXGEL, INC..
“On September 9, 2021, Yaakov Spinrad, Miranda J. Toledano and Adam Levy (the “ Board Appointees ”) were appointed to the board of directors”
Yaakov Spinrad was appointed as Director at NEXGEL, INC..
“On September 9, 2021, Yaakov Spinrad, Miranda J. Toledano and Adam Levy (the “ Board Appointees ”) were appointed to the board of directors”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.